HTA Methodology Shifts & Pricing Pressures

MarcusWelcome to Access Brief, the daily AI podcast on HEOR, HTA, and market access. I'm Marcus, with Sara. Today: HTA updates in the Middle East, Canadian pricing policy, RWE in Latin America, and HEOR for gene therapies in Asia. Let's get into it.

MarcusStarting with HTA bodies in the Middle East adopting more flexible frameworks for rare diseases. This signals recognition of unmet needs but creates methodological uncertainty. Saudi Arabia's new pilot allows shorter evidence packages for ultra-orphan drugs, while Jordan is incorporating partial QALY adjustments for pediatric populations. The risk? Inconsistent value assessments across the region.

SaraThat flexibility might be necessary for innovation, but it undermines comparability. When HTA bodies deviate from standard cost-per-QALY thresholds, it creates a patchwork where similar drugs face divergent access decisions. The commercial implications are messy—companies must now develop region-specific dossiers for markets that previously relied on centralized evidence.

MarcusWithout flexibility, we risk excluding innovations that don't fit traditional models. Middle Eastern HTA bodies are finally acknowledging that conventional metrics fail for ultra-rare conditions. The alternative is maintaining rigid frameworks that deny patients access to potentially life-changing treatments.

SaraThe burden shifts to sponsors to justify deviations, which strains resources. When HTA bodies redefine their own rules mid-process, it introduces regulatory unpredictability that complicates evidence generation strategies. This isn't evolution—it's fragmentation.

MarcusShifting to Canada's pricing policy. The Patented Medicine Prices Review Board is implementing stricter cost-containment measures for oncology drugs. New reference pricing models are targeting biologics with similar mechanisms, regardless of clinical differentiation. The impact? Pressure on premium pricing for novel therapies.

SaraThese measures reflect broader political priorities but ignore value differentiation. When reference pricing groups drugs by class rather than indication, it penalizes innovations that offer meaningful improvements over existing options. The commercial risk is real—companies may delay launches in Canada if reimbursement doesn't reflect clinical superiority.

MarcusThe alternative is unsustainable price growth. Canada's system is buckling under drug expenditure inflation, and reference pricing is a pragmatic response. The question isn't whether to control costs but how to do it without stifling innovation.

SaraThe how matters. By conflating therapeutic classes, policymakers undermine the entire value proposition framework. If HTA bodies can't distinguish between incremental and breakthrough innovations, the entire evidence ecosystem loses credibility.

MarcusThird topic: RWE integration in Latin America. Brazil's HTA agency is accepting real-world data for reimbursement decisions when RCTs are impractical, but data quality requirements remain inconsistent. Mexico's COFEPRIS now requires RWE validation for orphan drugs, while Chile's ISP uses it only for post-marketing surveillance. The result? Uneven adoption across the region.

SaraThe inconsistency creates evidence strategy nightmares. Sponsors must now tailor RWE approaches for each country, duplicating efforts and increasing costs. Worse, without standardized validation protocols, the risk of methodologically flawed submissions rises significantly.

MarcusRWE fills critical evidence gaps, especially for rare diseases and pediatric populations. Latin America's heterogeneity demands flexible approaches—not uniformity. The alternative is excluding entire patient populations from evidence generation.

SaraThe flexibility comes at the cost of reliability. When HTA bodies apply different RWE standards, it introduces arbitrariness into reimbursement decisions. That erodes trust in the entire HTA process.

MarcusFinally, gene therapy HEOR strategies in Asia. Japan's PMDA is developing specific frameworks for one-time curative treatments, incorporating cost-offset modeling for chronic disease management. South Korea's HIRA now accepts surrogate endpoints in early access programs for ultra-rare diseases. Singapore's HSA requires long-term follow-up plans for gene therapies.

SaraThese approaches acknowledge the unique economic profile of gene therapies but create reimbursement uncertainty. When HTA bodies demand long-term RWE for one-time treatments, it forces sponsors into perpetual data collection without clear value recognition.

MarcusThe alternative is maintaining traditional cost-per-QALY models that undervalue transformative therapies. Asia-Pacific countries are leading the way in adapting evidence frameworks to innovation—we should follow their lead.

SaraAdaptation without standardization risks creating more barriers. Until Asia-Pacific HTA bodies align on core principles, sponsors will face fragmented evidence requirements across the region.

MarcusSara, your contrarian views on methodological flexibility are noted. But rigid frameworks fail patients with unmet needs.

SaraMarcus, your defense of flexibility ignores the operational chaos it creates for evidence teams. Without standardization, HTA loses its purpose.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.